Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):874–880. doi: 10.1038/bjc.1996.451

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status.

N H Nielsen 1, C Arnerlöv 1, S O Emdin 1, G Landberg 1
PMCID: PMC2074748  PMID: 8826852

Abstract

Cyclin E is a G1 cyclin which has been proposed to be one of the key regulators of the important G1/S transition, and could consequently be a potential deregulated molecule in tumours. Recently, it has been observed that cyclin E is overexpressed in a variety of malignancies including breast cancer and that several isoforms of the protein exists. In this study we have characterised the cyclin E expression in 114 tumour specimens from patients with primary breast cancer using Western blotting. Various expression of cyclin E was observed among tumours and a group of 27 patients out of 100 patients with stage I-III disease, identified as having tumours with high cyclin E levels, had a significantly increased risk of death and relapse from breast cancer (P = 0.0002 and P = 0.015 respectively). Even in the subgroup of axillary node-negative patients the cyclin E level was of prognostic importance. There was also a strong association between cyclin E expression and oestrogen receptor status (P < 0.00001), and tumours with high cyclin E expression were in general oestrogen receptor negative, suggesting a potential role for cyclin E in mechanisms responsible for oestrogen-independent tumour growth.

Full text

PDF
874

Images in this article

876Figure 1
on p.876

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnane J., Gaudray P., Simon M. P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene. 1989 Nov;4(11):1389–1395. [PubMed] [Google Scholar]
  2. Arnerlöv C., Emdin S. O., Roos G., Angström T., Bjersing L., Angquist K. A., Jonsson H. Static and flow cytometric DNA analysis compared to histologic prognostic factors in a cohort of stage T2 breast cancer. Eur J Surg Oncol. 1990 Jun;16(3):200–208. [PubMed] [Google Scholar]
  3. Buckley M. F., Sweeney K. J., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., deFazio A., Watts C. K., Musgrove E. A., Sutherland R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993 Aug;8(8):2127–2133. [PubMed] [Google Scholar]
  4. Dou Q. P., Levin A. H., Zhao S., Pardee A. B. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res. 1993 Apr 1;53(7):1493–1497. [PubMed] [Google Scholar]
  5. Dulić V., Lees E., Reed S. I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 1992 Sep 25;257(5078):1958–1961. doi: 10.1126/science.1329201. [DOI] [PubMed] [Google Scholar]
  6. Dutta A., Chandra R., Leiter L. M., Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5386–5390. doi: 10.1073/pnas.92.12.5386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Feichter G. E., Mueller A., Kaufmann M., Haag D., Born I. A., Abel U., Klinga K., Kubli F., Goerttler K. Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer. Int J Cancer. 1988 Jun 15;41(6):823–828. doi: 10.1002/ijc.2910410608. [DOI] [PubMed] [Google Scholar]
  8. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  9. He J., Allen J. R., Collins V. P., Allalunis-Turner M. J., Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804–5807. [PubMed] [Google Scholar]
  10. Herman M. E., Katzenellenbogen B. S. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 1994 Nov 15;54(22):5867–5874. [PubMed] [Google Scholar]
  11. Horwitz K. B. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):295–302. doi: 10.1016/0960-0760(94)90271-2. [DOI] [PubMed] [Google Scholar]
  12. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  13. Keyomarsi K., Conte D., Jr, Toyofuku W., Fox M. P. Deregulation of cyclin E in breast cancer. Oncogene. 1995 Sep 7;11(5):941–950. [PubMed] [Google Scholar]
  14. Keyomarsi K., O'Leary N., Molnar G., Lees E., Fingert H. J., Pardee A. B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994 Jan 15;54(2):380–385. [PubMed] [Google Scholar]
  15. Keyomarsi K., Pardee A. B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112–1116. doi: 10.1073/pnas.90.3.1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., Roberts J. M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 1991 Sep 20;66(6):1217–1228. doi: 10.1016/0092-8674(91)90044-y. [DOI] [PubMed] [Google Scholar]
  17. Koff A., Giordano A., Desai D., Yamashita K., Harper J. W., Elledge S., Nishimoto T., Morgan D. O., Franza B. R., Roberts J. M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992 Sep 18;257(5077):1689–1694. doi: 10.1126/science.1388288. [DOI] [PubMed] [Google Scholar]
  18. Kornblau S. M., Xu H. J., Zhang W., Hu S. X., Beran M., Smith T. L., Hester J., Estey E., Benedict W. F., Deisseroth A. B. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood. 1994 Jul 1;84(1):256–261. [PubMed] [Google Scholar]
  19. Lammie G. A., Fantl V., Smith R., Schuuring E., Brookes S., Michalides R., Dickson C., Arnold A., Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991 Mar;6(3):439–444. [PubMed] [Google Scholar]
  20. Leach F. S., Elledge S. J., Sherr C. J., Willson J. K., Markowitz S., Kinzler K. W., Vogelstein B. Amplification of cyclin genes in colorectal carcinomas. Cancer Res. 1993 May 1;53(9):1986–1989. [PubMed] [Google Scholar]
  21. Matsushime H., Roussel M. F., Ashmun R. A., Sherr C. J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell. 1991 May 17;65(4):701–713. doi: 10.1016/0092-8674(91)90101-4. [DOI] [PubMed] [Google Scholar]
  22. Meyer J. S., Province M. A. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer. 1994 Oct 15;74(8):2287–2299. doi: 10.1002/1097-0142(19941015)74:8<2287::aid-cncr2820740813>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  23. Motokura T., Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev. 1993 Feb;3(1):5–10. doi: 10.1016/s0959-437x(05)80334-x. [DOI] [PubMed] [Google Scholar]
  24. Motokura T., Bloom T., Kim H. G., Jüppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512–515. doi: 10.1038/350512a0. [DOI] [PubMed] [Google Scholar]
  25. Musgrove E. A., Hamilton J. A., Lee C. S., Sweeney K. J., Watts C. K., Sutherland R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol. 1993 Jun;13(6):3577–3587. doi: 10.1128/mcb.13.6.3577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Musgrove E. A., Lee C. S., Buckley M. F., Sutherland R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8022–8026. doi: 10.1073/pnas.91.17.8022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. doi: 10.1073/pnas.91.23.11045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Otsuki T., Clark H. M., Wellmann A., Jaffe E. S., Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995 Apr 1;55(7):1436–1440. [PubMed] [Google Scholar]
  29. Resnitzky D., Gossen M., Bujard H., Reed S. I. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 1994 Mar;14(3):1669–1679. doi: 10.1128/mcb.14.3.1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schuuring E., Verhoeven E., van Tinteren H., Peterse J. L., Nunnink B., Thunnissen F. B., Devilee P., Cornelisse C. J., van de Vijver M. J., Mooi W. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992 Oct 1;52(19):5229–5234. [PubMed] [Google Scholar]
  31. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  32. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  33. Sutherland R. L., Watts C. K., Musgrove E. A. Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):99–106. doi: 10.1016/0960-0760(93)90062-2. [DOI] [PubMed] [Google Scholar]
  34. Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  35. Tassan J. P., Schultz S. J., Bartek J., Nigg E. A. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol. 1994 Oct;127(2):467–478. doi: 10.1083/jcb.127.2.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Theillet C., Adnane J., Szepetowski P., Simon M. P., Jeanteur P., Birnbaum D., Gaudray P. BCL-1 participates in the 11q13 amplification found in breast cancer. Oncogene. 1990 Jan;5(1):147–149. [PubMed] [Google Scholar]
  37. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671. doi: 10.1038/369669a0. [DOI] [PubMed] [Google Scholar]
  38. Watts C. K., Sweeney K. J., Warlters A., Musgrove E. A., Sutherland R. L. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1994;31(1):95–105. doi: 10.1007/BF00689680. [DOI] [PubMed] [Google Scholar]
  39. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995 May 5;81(3):323–330. doi: 10.1016/0092-8674(95)90385-2. [DOI] [PubMed] [Google Scholar]
  40. Williams M. E., Swerdlow S. H., Meeker T. C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia. 1993 Sep;7(9):1437–1440. [PubMed] [Google Scholar]
  41. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  42. van Agthoven T., van Agthoven T. L., Portengen H., Foekens J. A., Dorssers L. C. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res. 1992 Sep 15;52(18):5082–5088. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES